Consenso uruguayo de manejo del infarto agudo de ... - SciELO

More documents

Recommendations

Info

72. Steg PG, Bonnefoy E, Chabaud S, Lapostolle F, Dubien PY, Cristofini P, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation. 2003; 108: 2851-6. 73. Widimsky P, Budesinsky T, Vorac D, Groch L, Zelizko M, Aschermann M, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction: Final results of the randomized national multicentre trial--PRAGUE-2. Eur Heart J 2003; 24: 94-104. 74. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything?. Am J Cardiol 2003; 92: 824-6. 75. Wu AH, Parsons L, Every NR, Bates ER, for the Second National Registry of Myocardial Infarction. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 2002; 40: 1389-94. 76. Hochman JS, Sleeper LA, Webb JG, et al, for the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) Investigators. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999; 341: 625- 34. 77. Hochman JS, Sleeper LA, White HD, Dzavik V, Wong SC, Menon V, et al. One-year survival following early revascularization for cardiogenic shock. JAMA 2001; 285: 190-2. 78. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82. 79. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003; 349: 733-42. 80. Aversano T, Aversano LT, Passamani E, Knatterud GL, Terrin ML, Williams DO, et al. Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA 2002; 287: 1943-51. 81. Widimský P, Groch L, Zelízko M, Aschermann M, Bednár F, Suryapranata H. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory: The PRAGUE study. Eur Heart J 2000; 21: 823-31. 82. Vermeer F, Oude-Ophuis AJ, vd-Berg EJ, Brunninkhuis LG, Werter CJ, Boehmer AG, et al. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA
facilities: a safety and feasibility study. Heart 1999; 82: 426-31. 83. Grines CL, Westerhausen DR, Grines LL, Hanlon JT, Logemann TL, Niemela M, et al. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. J Am Coll Cardiol 2002; 39: 1713-9. 84. Ellis SG, da-Silva ER, Heyndrickx G, Talley JD, Cernigliaro C, Steg G, et al. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction. Circulation 1994; 90: 2280-4. 85. Goldman LE, Eisenberg MJ. Identification and management of patients with failed thrombolysis after acute myocardial infarction. Ann Intern Med 2000; 132: 556-65. 86. Stone GW, Grines CL, Cox DA, et al, for the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346: 957-66. 87. Montalescot G, Barragan P, Wittenberg O, et al, for the Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up (ADMIRAL) Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895- 903. 88. Antoniucci D, Rodriguez A, Hempel A, Valenti R, Migliorini A, Vigo F, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003; 42: 1879-85. 89. Herrmann HC, Moliterno DJ, Ohman EM, Stebbins AL, Bode C, Betriu A, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED(GUSTO-4 Pilot) Trial. J Am Coll Cardiol 2000; 36: 1489-96. 90. Ross AM, Coyne KS, Reiner JS, et al, for the Plasminogenactivator Angioplasty Compatibility Trial (PACT) investigators. A randomized trial comparing primary angioplasty with a strategy of shortacting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. J Am Coll Cardiol 1999; 34: 1954- 62. 91. Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, Vazquez N, Blanco J, Alonso-Briales J, et al. Prospective randomized trial comparing a routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet 2004; 364: 1045-53. 92. Kastrati A, Mehilli J, Schlotterbeck K, et al, for the Bavarian
Page 1 and 2:
CONSENSO REV URUG CARDIOL 2006; 21
Page 3 and 4:
Gabriel Vanerio GRUPO 9. MANEJO AL
Page 5 and 6:
3. CONSIDERACIONES PREVIAS La magni
Page 7 and 8:
Se resalta, además, que sería má
Page 9 and 10:
ealizada muy tempranamente, puede n
Page 11 and 12: El efecto beneficioso de los nitrat
Page 13 and 14: Valsartan y Candesartan han demostr
Page 15 and 16: segmento ST como signo isquémico,
Page 17 and 18: al menos 36 angioplastias primarias
Page 19 and 20: la heparina no era necesaria como c
Page 21 and 22: En virtud de estas consideraciones
Page 23 and 24: los pacientes de alto riesgo (86-88
Page 25 and 26: primeras 48 horas se individualizar
Page 27 and 28: insuficiencia cardíaca o diabetes
Page 29 and 30: elementos de hipoperfusión perifé
Page 31 and 32: g. luego de IAM con significativa d
Page 33 and 34: El cateterismo derecho puede aporta
Page 35 and 36: . en pacientes con monitorización
Page 37 and 38: a. Betabloqueantes vía oral o intr
Page 39 and 40: . Bloqueo auriculoventricular trans
Page 41 and 42: Si el paciente no tiene ninguno de
Page 43 and 44: tratamiento adecuado. La angioplast
Page 45 and 46: no sostenida, etcétera. El estudio
Page 47 and 48: pacientes indefinidamente* Betabloq
Page 49 and 50: incrementar la actividad de la vida
Page 51 and 52: fumadores desde la etapa de hospita
Page 53 and 54: catalogarse el valor de LDL como ba
Page 55 and 56: las posibilidades de infarto y acci
Page 57 and 58: Infarction: A Meta-analysis. JAMA 2
Page 59 and 60: Coll Cardiol 1998; 32: 634-40. 38.
Page 61: 61. Pfeffer MA, McMurray JJ, Velazq
Page 65 and 66: with the low-molecular-weight hepar
Page 67 and 68: evaluation and management of chroni
Page 69 and 70: 147. Teo KK, Yusuf S, Furberg CD. E
Page 71 and 72: 169. Bardy GH, Lee KL, Mark DB, Poo
Page 73 and 74: 192. Fiore MC, Smith SS, Jorenby DE
Page 75: Hlatky M, et al. Cardiovascular dis
show all

Consenso uruguayo de manejo del infarto agudo de ... - SciELO

Create successful ePaper yourself

Delete template?

Save as template?